MAP2K7 and cancer: Molecular and pharmacological studies have shown that MEK and ERK are required for the transforming activities of RAS and various other oncogenes, and preclinical data support an important role for the RAS-ERK pathway in cancer biology and its potential as a therapeutic target in human cancers [36].